Congress finds the following:
(1)
Researchers, scientists, doctors, epidemiologists, and others around the world have worked tirelessly and collaboratively to develop lifesaving vaccines to combat the coronavirus by reducing the likelihood of transmission, building immune resiliency, avoiding hospitalizations, and reducing the likelihood of death.
(2)
Through the academic, research and analytic expertise of universities and their faculty, researchers, and students, their efforts contributed to providing valuable information to the public on the severity of the coronavirus worldwide and, in some cases, contributed to vaccine development.
(3)
Several of the resulting vaccines represent historic breakthroughs in biopharmaceutical technology, which are predicated on years of leading research conducted in laboratories and hospitals that benefit from the significant financial investment of United States taxpayers through the Department of Health and Human Services, the National Institutes of Health, including the National Institute of Allergy and Infectious Diseases, and the Biomedical Advanced Research and Development Authority.
(4)
These professionals worked under record timelines to develop safe, effective vaccines demonstrated in trials and granted emergency use authorization by the Food and Drug Administration, outpacing the typical vaccine development timeframe of 5 to 10 years and beating the previous record by 3 years.
(5)
These remarkable achievements in medical science will have positive implications for future vaccine development, helping to combat new viruses, leading to improvements in health and well-being.
(6)
The tremendous efforts in vaccine development can be celebrated and attributed to building diverse teams, including the notable efforts of many individuals across the planet.
(7)
Vaccines authorized for emergency use in the United States benefitted greatly from global cooperation, strategic partnerships, and collaboration with publicly funded agencies and research capabilities of the academic community.
(8)
As a result of the collaborative efforts, people around the world are benefitting from the administration of vaccines, although work remains to support governments around the world in ensuring vaccines are equitably distributed.
(9)
The United States, including through cooperation with bilateral and multilateral partnerships, can help scale up manufacturing and distribution to all corners of the globe.
(10)
The vaccines developed are contributing to the safety of people of the United States, rebuilding the United States economy, and the reunion of families.